Sotorasib in KRAS G12C-Mutated Advanced Pancreatic Cancer: CodeBreaK 100 Trial

On December 21, 2022, Dr. John H. Strickler and colleagues published the results of the CodeBreaK 100 Phase 1/2 clinical trial in The New England Journal of Medicine. This study evaluated the efficacy and safety of Sotorasib (Lumakras), a first-in-class KRAS G12C inhibitor, in patients with heavily pretreated advanced pancreatic cancer harboring the KRAS G12C mutation.

Study Design: CodeBreaK 100 Trial

The trial included 38 patients with KRAS G12C-mutated pancreatic cancer who had progressed on prior systemic therapies. All patients received Sotorasib at a dose of 960 mg orally once daily. The primary endpoint was the objective response rate (ORR).

Key Efficacy Results

• Objective Response Rate (ORR): 21%
• Disease Control Rate: 84%
• Median Progression-Free Survival (PFS): 4.0 months
• Median Overall Survival (OS): 6.9 months

While the ORR may seem modest, it represents a significant signal in a disease where later-line options are extremely limited and KRAS mutations were previously considered "undruggable."

Safety and Tolerability

Sotorasib demonstrated a favorable safety profile:

• Adverse Event Incidence: 42% of patients experienced treatment-related side effects.
• Grade 3+ Side Effects: Occurred in only 16% of patients.
• No treatment-related deaths were reported.

Conclusion

The authors concluded that Sotorasib monotherapy provides clinically meaningful antitumor activity with a manageable safety profile in patients with pretreated KRAS G12C-mutated advanced pancreatic cancer. These findings establish KRAS G12C as a viable therapeutic target in pancreatic cancer, similar to results seen in non-small cell lung cancer.

Source: The New England Journal of Medicine - Sotorasib in Pancreatic Cancer

#PancreaticCancer #KRASG12C #Sotorasib #Lumakras #CodeBreaK100 #PrecisionMedicine #CancerResearch

Figure 1

Figure 2

Figure 3

Figure 4